SEC Form 4													
FORM 4 UNITED			STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			ENT OF CHANGES IN BENEFICIAL OWNE iled pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							CMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] Kelly Timothy Edwin			2. Issuer Name and Ticker or Trading Symbol <u>Praxis Precision Medicines, Inc.</u> [PRAX]						(Chec	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Financial Officer			
(Last) (First) (Middle) C/O PRAXIS PRECISION MEDICINES, INC. 99 HIGH STREET, 30TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 01/12/2023										
(Street) BOSTON MA	02110		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indi Line) X	X Form filed by One Reporting Person Form filed by More than One Reporting			
(City) (State)	(Zip)									Person			
1	lable I - Noi	n-Deriva	tive S	ecurities Acq	uired,	Disp	posed of, c	or Bene	eficially	Owned			
Dat		2. Transac Date (Month/Da		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Table II -	Derivativ	ve Ser	curities Acqui	Code	v Visno		(A) or (D) Benef	Price	Transaction(s) (Instr. 3 and 4)			

(e.g., puts, calls, warrants, options, convertible securities)

Date Exercisable

01/12/2023

(D)

6. Date Exercisable and Expiration Date (Month/Day/Year)

Expiration

01/12/2033

Date

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

4. Transaction Code (Instr. 8)

v

(A)

42,455⁽¹⁾

Code

A

Buy) Explanation of Responses:

\$2.96

2. Conversion

or Exercise Price of Derivative

Security

1. Mr. Kelly opted to receive this option grant in lieu of a cash bonus for the fiscal year ended December 31, 2022.

3A. Deemed Execution Date, if any (Month/Day/Year)

Remarks:

Stock Option (Right to

1. Title of Derivative Security (Instr. 3)

/s/ Alex Nemiroff, as Attorneyin-Fact

01/13/2023

42,455

9. Number of derivative Securities Beneficially

Owned Following Reported Transaction(s)

(Instr. 4)

10.

Ownership

Form: Direct (D)

or Indirect

(I) (Instr. 4)

D

8. Price of Derivative

Security (Instr. 5)

\$<mark>0</mark>

11. Nature of Indirect Beneficial Ownership

(Instr. 4)

** Signature of Reporting Person Date

7. Title and Amount of Securities

Underlying Derivative Security (Instr. 3 and 4)

Amount

Number

Shares

42,455

of

Title

Commo Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

3. Transaction Date

(Month/Day/Year)

01/12/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.